Hiddo J. L. Heerspink, PharmD, PhD, discusses SOLSTICE elecoglipron data, finerenone in FSGS, and glucagon’s kidney effects from ASN Kidney Week 2026.
|Articles|February 11, 2022
Daily OTC Pearl: Joint Complex
Author(s)Saro Arakelians, PharmD
Joint Complex supports joint function and lubrication, as well as tissue hydration.
Advertisement
OTC/Lifestyle Pearl of the Day: Joint Complex
Indication: Supports overall joint health, mobility, and comfort.
Insight:
- Joint Complex supports joint function and comfort, as well as tissue hydration and joint lubrication.
- Directions: As a dietary supplement, take 3 caplets in the morning with food.
- Cautions: This product is only intended for healthy adults, 18 years of age or older.
- Keep out of reach of children
- Do not use if pregnant or nursing.
- Discontinue use and consult a health care professional if you experience any adverse reaction to this product.
- Do not use if safety seal is broken or missing.
- Storage: Store in a cool, dry place.
Source:
Advertisement
Related to this article
Pharmacy performance measures should recognize clinical interventions, patient counseling, prescriber collaboration, and outcomes—not prescription volume alone.
CMS’s GLP-1 Bridge demo bypasses Part D to cover select obesity drugs, with a $50 monthly copay, PA workflow, and strict eligibility through 2027.
Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.
Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Beyond Prescription Volume: Measuring the Pharmacist’s Value
2
Medicare GLP-1 Bridge Runs Outside Part D and Pharmacy Teams Need a Different Workflow
3
FDA Approves Talazoparib With Enzalutamide for HRR-Mutated Metastatic Prostate Cancer
4
GLP-1 RAs, Finerenone, and CKD: Key Data From Kidney Week 2026
5